Objective: It was the aim of this study to develop Cyclosaplin analogs and assess the anticancer effects of those analog peptides on MDA-Mb-231 as well as K562 cell lines. The analogs of Cyclosaplin peptide (Cyclosaplin-2A and Cyclosaplin-7G) were designed and then investigated by online web server predictor AntiCP. The analog peptides were applied to MDA-MB-231 and K562 cells in various concentrations and for various periods of time. The anticancer potential was confirmed by the MTT assay. Hemolytic activity also was assessed. In order to investigate the apoptotic effects of peptides on cancer cells, various tests such as morphological examination, Giemsa test, and DNA fragmentation were performed. Lactate dehydrogenase leakage also was examined to confirm the effects of analogs.
Results: Our experimental and computational data show that the analog peptides have anticancer potential. The MTT assay and morphological study confirmed the anticancer effects. Other tests also confirmed the anticancer effect of the analog peptides. According to hemolytic assays, none of the analog peptides possess any hemolytic activity against human erythrocytes, indicating the compounds are not toxic for normal cells. Analog peptides found in this study were shown to have anticancer potential on two human cancer cell lines.